About this item:

143 Views | 179 Downloads

Author Notes:

Correspondence: Isolde A.R. Kuijlaars, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Email: i.a.r.kuijlaars-2@umcutrecht.nl

Author contributions: IAR Kuijlaars, J van der Net, BM Feldman and K Fischer contributed to the design of the study; IAR Kuijlaars performed the statistical analyses; IAR Kuijlaars wrote the first draft of the paper; all authors contributed to interpretation of the data, modification of statistical analyses and the writing of the manuscript.

Acknowledgements: The authors would like to thank A Willemsen and O Versloot for their help in the organization of the expert meeting.

Disclosures: J van der Net, BM Feldman, SM Funk, P Hilliard, M Manco‐Johnson and P Petrini are co‐inventors of the Haemophilia Joint Health Score (HJHS).

CL Kempton has received honoraria for consulting and participating in advisory boards from Spark Therapeutics, Octapharma, Genetech, and Pfizer and research support from Novo Nordisk.

MJ Manco‐Johnson has received honoraria for Advisory Boards from BioMarin, BioVerativ, CSL Behring, Novo Nordisk, Sparks and Takeda. P Petrini has acted as a paid consultant to Roche, Baxalta, Sobi and Baxter. The other authors have no competing interests.

Subjects:

Research Funding:

None declared

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Hematology
  • expert opinion
  • haemophilia
  • joints
  • outcome measures
  • physical examination
  • Prophylaxis

Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS

Show all authors Show less authors

Tools:

Journal Title:

Haemophilia

Volume:

Volume 26, Number 6

Publisher:

, Pages 1072-1080

Type of Work:

Article | Final Publisher PDF

Abstract:

Introduction: The Hemophilia Joint Health Score (HJHS) was developed to detect early changes in joint health in children and adolescents with haemophilia. The HJHS is considered by some to be too time consuming for clinical use and this may limit broad adoption. Aim: This study was a first step to develop a shorter and/or more convenient version of the HJHS for the measurement of joint function in children and young adults with haemophilia, by combining real-life data and expert opinion. Methods: A cross-sectional multicenter secondary analysis on pooled data of published studies using the HJHS (0-124, optimum score 0) in persons with haemophilia A/B aged 4-30 was performed. Least informative items, scoring options and/or joints were identified. An expert group of 19 international multidisciplinary experts evaluated the results and voted on suggestions for adaptations in a structured meeting (consensus set at ≥ 80%). Results: Original data on 499 persons with haemophilia from 7 studies were evaluated. Median age was 15.0 years [range 4.0-29.9], 83.2% had severe haemophilia and 61.5% received prophylaxis. Median (IQR) HJHS total was 6.0 (1.0-17.0). The items 'duration swelling' and 'crepitus' were identified as clinically less informative and appointed as candidates for reduction. Conclusion: Analysis of 499 children and young adults with haemophilia showed that the HJHS is able to discriminate between children and adults and different treatment regimens. Reduction of the items 'duration swelling' and 'crepitus' resulted in the HJHSshort, which had the same discriminative ability. Additional steps are needed to achieve a substantially shorter HJHS assessment.

Copyright information:

© 2020 The Authors. Haemophilia published by John Wiley & Sons Ltd.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/rdf).
Export to EndNote